Rebus Holdings, Inc.
company.status.inactiveCIK 1421204fmd_0322C19V584D1WKZSRTK5JKM7EManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2004 to Jun 30, 2023, 59 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | – | 0 | 0 | 0 | (5) | (1) | (1) | (0) | (1) | (0) |
| Research and development | 4 | 4 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 6 | 7 | 6 | 3 | 6 | 1 | 1 | 2 | 1 | 1 |
| Operating income | (6) | (7) | (6) | (3) | (6) | (1) | (1) | (2) | (1) | (1) |
| Interest expense | 0 | (0) | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (5) | (7) | (6) | (3) | (11) | (0) | (1) | (6) | 3 | (1) |
| Income tax expense | 0 | 0 | 0 | – | – | – | 0 | 0 | 0 | – |
| Net income from continuing operations | (5) | (7) | (6) | – | – | – | (1) | (6) | 3 | – |
| Net income | (5) | (7) | (6) | (3) | (11) | (0) | (1) | (6) | 3 | (1) |
| Net income to common shareholders | – | – | – | (4) | (13) | (0) | (1) | (6) | 0 | – |